Could Oncomed Pharmaceuticals Inc (NASDAQ:OMED) Skyrocket? The Stock Had Too Little Sellers

October 11, 2018 - By Louis Casey

Investors sentiment decreased to 0.96 in 2018 Q2. Its down 0.21, from 1.17 in 2018Q1. It is negative, as 6 investors sold OncoMed Pharmaceuticals, Inc. shares while 17 reduced holdings. 8 funds opened positions while 14 raised stakes. 17.82 million shares or 3.12% less from 18.39 million shares in 2018Q1 were reported.
10,429 are held by Art Advsrs Ltd Limited Liability Company. Moreover, Renaissance Tech Ltd Liability has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Plante Moran Advsrs Limited Com owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 380 shares. Primecap Mngmt Co Ca holds 0.01% or 5.56M shares. Spark Invest Mgmt Ltd, New York-based fund reported 134,400 shares. Tower Rech Capital Ltd Com (Trc) accumulated 5,291 shares. Alyeska Gru Inc L P holds 0.01% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 534,309 shares. First Eagle Mgmt Llc holds 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 219,420 shares. Nj State Employees Deferred Compensation Plan holds 38,000 shares. Perceptive Advisors Ltd Liability Company has invested 0.16% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). The Vermont-based Birchview Lp has invested 0.15% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Schwab Charles Investment Mgmt holds 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 61,985 shares. State Street Corporation has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Group One Trading Lp holds 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) or 8,500 shares. Bvf Inc Il owns 4.10 million shares.

Since April 24, 2018, it had 0 insider purchases, and 5 selling transactions for $58,301 activity. Gurney Austin also sold $10,848 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) shares. Hager Alicia J. had sold 4,051 shares worth $10,848 on Tuesday, April 24. $12,202 worth of stock was sold by Lewicki John A. on Tuesday, April 24. On Tuesday, April 24 Stagg Robert sold $10,848 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) or 4,051 shares.

The stock of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) registered a decrease of 4.73% in short interest. OMED’s total short interest was 241,700 shares in October as published by FINRA. Its down 4.73% from 253,700 shares, reported previously. With 48,800 shares average volume, it will take short sellers 5 days to cover their OMED’s short positions. The short interest to Oncomed Pharmaceuticals Inc’s float is 1.13%.

The stock increased 2.94% or $0.06 during the last trading session, reaching $2.1. About 6,929 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 39.47% since October 11, 2017 and is downtrending. It has underperformed by 55.09% the S&P500.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $80.85 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

More notable recent OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) news were published by: Benzinga.com which released: “55 Biggest Movers From Yesterday” on October 04, 2018, also Globenewswire.com with their article: “OncoMed Provides Update on Navicixizumab Partnership” published on September 20, 2018, Globenewswire.com published: “OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of …” on October 09, 2018. More interesting news about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) were released by: Globenewswire.com and their article: “OncoMed Announces Publication of Phase 1a Data of Navicixizumab” published on September 24, 2018 as well as Uk.Finance.Yahoo.com‘s news article titled: “Can OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improve Your Portfolio Returns?” with publication date: September 13, 2018.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>